ABSTRACT
OBJECTIVES: Data on multidisciplinary programs dedicated to home parenteral nutrition (HPN) in Latin America are limited. This study describes the results of the first multidisciplinary pediatric intestinal rehabilitation program for HPN at a public tertiary hospital in Brazil. METHODS: We retrospectively reviewed patients aged 0-18 years with intestinal failure (IF) who required parenteral nutrition (PN) for >60 days between January/2014 and December/2020. RESULTS: Fifty-four patients were discharged on HPN (15 achieved enteral autonomy, 34 continued on HPN at the end of the study, 1 underwent intestinal transplantation, and 4 died). The median (IQR) age at the study endpoint of patients who achieved enteral autonomy was 14.1 (9.7-19) versus 34.7 (20.4-53.9) months in those who did not achieve enteral autonomy. Overall prevalence of catheter-related thrombosis was 66.7% and catheter-related bloodstream infection rate was 0.39/1000 catheter-days. Intestinal failure-associated liver disease (IFALD) was present in 24% of all patients; none of the patients who achieved enteral autonomy had IFALD. All patients showed significant improvement in anthropometric parameters during the HPN period. The sociodemographic characteristics of the patients' family members were mothers less than 20 years old (7.5%), schooling time more than 10 years (55.5%), and household income between 1 and 3 times the minimum wage (64.8%). The 5-year survival rate for HPN is 90%, and 27.7% of patients achieve enteral autonomy. CONCLUSION: The treatment of pediatric patients with IF followed by a multidisciplinary pediatric intestinal rehabilitation program with HPN is feasible and safe in the Brazilian public health system.
Subject(s)
Intestinal Diseases , Liver Diseases , Parenteral Nutrition, Home , Adult , Brazil , Child , Humans , Intestinal Diseases/etiology , Intestinal Diseases/therapy , Liver Diseases/etiology , Parenteral Nutrition, Home/adverse effects , Retrospective Studies , Young AdultABSTRACT
Objetivo: avaliar a prevalência de hepatite viral A (HVA) em crianças e adolescentes portadores de doenças crônicas do fígado, em um serviço de hepatologia pediátrica. Métodos: entre maio de 1999 e fevereiro de 2001, foi estudada a prevalência de anticorpos anti-HVA total em 60 crianças e adolescentes, entre 1 e 16 anos de idade, portadoras de hepatopatias crônicas, provenientes da unidade de gastroenterologia pediátrica e programa de transplante hepático infantil do serviço de pediatria do Hospital de Clínicas de Porto Alegre. O anti-HVA, realizado através de um teste laboratorial comercialmente disponível em nosso meio (Abbott - MEIA HAVAB - sistema AXSYM), foi determinado e relacionado com a idade, com o sexo, com a cor, com o diagnóstico etiológico da hepatopatia e com a renda familiar dos pacientes.Resultados: apenas uma criança de 1 ano, portadora de atresia biliar, foi excluÝda do estudo por apresentar anti-HVA indeterminado, em duas ocasiões. Das 59 crianças restantes, 14 (24por cento) apresentavam resultados positivos para o anti-HVA total. As idades dos pacientes com anti-HVA positivos variaram de 1 a 16 anos (x= 7, 7 anos e mediana 8,5 anos). NÒo houve diferença significante entre idade, sexo e cor entre os grupos positivo e negativo. A renda familiar foi menor no grupo dos pacientes anti-HVA positivo, mas nÒo mostrou diferença estatÝstica significante. A diferença de prevalÛncia de anti-HVA entre as etiologias das hepatopatias estß, provavelmente, relacionada Ó idade mais do que ao diagnóstico. Conclusões: na populaçÒo estudada,...
Subject(s)
Humans , Male , Female , Child , Adolescent , Hepatitis A , Hepatitis Antibodies , Liver Diseases , PrevalenceABSTRACT
OBJECTIVE: To evaluate the prevalence of Hepatitis A virus (HAV) in children and adolescents with chronic liver disease in a unit of pediatric hepatology. METHODS: Between May 1999 and February 2001, we studied the prevalence of anti-HAV in 60 children and adolescents with chronic liver disease, aged between 1 and 16 years, from the Unit of Pediatric Hepatology of the Hospital de Clínicas de Porto Alegre. The total anti-HAV was determined by a commercially available competitive ELISA method (Abbott), and compared with age, sex, race, etiologic diagnosis and family income of each patient. RESULTS: A one-year old child was not included in the study because she presented twice with undetermined anti-HAV results. Among the other 59 patients, 14 (24%) presented a positive result of total anti-HAV. The ages of test-positive subjects varied between 1 and 16 years old (mean=7.7 years, median=8.5). The differences between positive and negative groups in relation to age, sex and race were not statistically significant. Family income was lower in anti-HAV positive patients, but this difference was not significant. The differences between the etiologies of liver diseases were probably more related to the age than to the etiologies of the diseases. CONCLUSIONS: In the studied population, the majority (76%) of children and adolescents with chronic liver disease are susceptible to hepatitis A virus infection and, consequently, they could present a more severe disease or even fulminant hepatitis A. We strongly suggest that these subjects receive Hepatitis A inactivated vaccine.
